Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pharma (ARWR) ENaC News 'Not Thesis Changing', RBC Says; PT Lowered to $83

July 2, 2021 12:16 PM EDT

RBC Capital analyst Luca Issi lowered the price target on Arrowhead Pharma (NASDAQ: ARWR) to $83.00 (from $90.00) while maintaining a Outperform rating following news the company is voluntarily pausing the Phase I/II trial for ENaC due to local lung inflammation seen in rats.... More

Arrowhead Pharma (ARWR) Defended at Citi Following ENAC Setback

July 2, 2021 10:02 AM EDT

Citi analyst Mohit Bansal came out to defend Arrowhead Pharma (NASDAQ: ARWR) amid the sharp drop in the stock after pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with... More

Arrowhead (ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study

July 2, 2021 7:45 AM EDT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study

... More